Volume dodolan mangsa ngarep perusahaan: Y-mAbs Therapeutics, Inc. (YMAB)

Y-mAbs Therapeutics Inc - logo grafis emiten YMAB

Y-mAbs Therapeutics (YMAB) is actively scaling its commercial footprint by expanding its pipeline of pediatric oncology drugs. Insurance coverage for critical pathologies ensures business stability, while AI enhances the efficiency of antibody development. The company's projected sales levels reflect expected cash flow dynamics, where the current parameter value is 0.09, confirming the potential for growth in the issuer's market value.

Volume dodolan mangsa ngarep perusahaan: Y-mAbs Corp (YMAB) kanggo 04.07.2022 - 27.09.2025

Rincian analitis perusahaan Y-mAbs Corp (YMAB)

- rega saiki lan proyeksi nilai saham:
Analisis dhasar perusahaan:Y-mAbs Therapeutics, Inc. YMAB
Produk merek YmAbs

To assess the operational resilience of assets, the investor analyzes the alignment of market expectations with actual commercial data, as expressed by the value of 0.09. This projected sales revenue allows for tracking the scaling efficiency of the targeted antibody portfolio within US hospitals and through distributors, identifying deviations from the investment mandate prior to the publication of financial statements to protect capital from drawdowns for Y-mAbs Therapeutics (YMAB).

Pesaing langsung

Prakiraan volume dodolan ONC|HALO (Halozyme) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan RVMD (revmed.com)|Dodolan mangsa ngarep perusahaan Ascentage (AAPG)|CGON: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan UroGen Pharma Ltd.|BCAX: Prakiraan volume dodolan|PSNL - Dodolan mangsa ngarep perusahaan|ERAS (Erasca Oncology) - Prakiraan volume dodolan|Prakiraan volume dodolan Delcath Systems, Inc.|Prakiraan volume dodolan AURA|Prakiraan pendapatan perusahaan CADL (Candel)|Accuray, Inc. - Volume dodolan mangsa ngarep perusahaan|SELLAS Life Sciences Group Inc. - Prakiraan pendapatan perusahaan|ACTU: Volume dodolan mangsa ngarep perusahaan|Volume dodolan sing dikarepake perusahaan Citius Oncology Inc|HURA: Prakiraan volume dodolan|TARA: Prakiraan volume pendapatan perusahaan|FATE (fatetherapeutics.com) - Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Aadi Bioscience Inc (WHWK)|Prakiraan volume dodolan TCRX|CSBR - Volume dodolan sing dikarepake perusahaan|Prakiraan volume dodolan XBIT (XBiotech Inc.)|CEL-SCI Corporation (CVM) - Volume dodolan sing dikarepake perusahaan|OSTX: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan RADX (Radiopharm Theranostics)|Artiva (ARTV) - Prakiraan pendapatan perusahaan|ANL: Prakiraan volume pendapatan perusahaan|VERU (Veru Corporation) - Prakiraan volume dodolan|Volume dodolan sing dikarepake perusahaan Tempest Therapeutics, Inc. TPST|Prakiraan volume dodolan XLO|Renovaro - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Mural Bio MURA|KAPA: Prakiraan pendapatan perusahaan|OnKure Therapeutics - Prakiraan volume dodolan|Dodolan mangsa ngarep perusahaan w2.cytomed.sg GDTC|CRIS: Prakiraan volume dodolan|Volume dodolan mangsa ngarep perusahaan Apollomics Inc.|THAR (Tharimmune Corporation) - Prakiraan volume dodolan|Prakiraan volume dodolan Advanced Biomed Inc|Prakiraan volume dodolan GNPX|Volume dodolan mangsa ngarep perusahaan Calidi Biotherapeutics Inc. CLDI|Prakiraan pendapatan perusahaan Sunshine Biopharma Inc. SBFM|Dodolan mangsa ngarep perusahaan Xenetic Biosciences (XBIO)|SLRX - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Kitov Pharma|AON (AONC) - Prakiraan pendapatan perusahaan|Volume dodolan mangsa ngarep perusahaan BeiGene|Prakiraan pendapatan perusahaan checkpointtx.com|Prakiraan pendapatan perusahaan ELEV (Elevation Oncology)|Prakiraan volume dodolan ICAD|Ikena Oncology - Prakiraan pendapatan perusahaan|Prakiraan pendapatan perusahaan Notable Labs, Ltd. NTBL|VIRX: Prakiraan pendapatan perusahaan|MOR - Prakiraan pendapatan perusahaan|NAYA Bio (NAYA) - Volume dodolan mangsa ngarep perusahaan|AAPGV: Prakiraan volume dodolan